GeoVax Gedeptin Synergizes with Checkpoint Inhibitors for Complete Tumor Regression in TNBC Models
GOVX•A peer-reviewed study in JCI Insight showed intratumoral PNP/F-araAMP therapy achieved complete regression of PNP-expressing TNBC tumors and induced responses in untreated distant lesions in BALB/c mice. Combining subcurative F-araAMP with immune checkpoint inhibitors yielded substantial tumor burden reductions and complete regressions in resistant models, supporting Gedeptin’s immuno-oncology potential.
1. Intratumoral Gedeptin Therapy in TNBC Models
In BALB/c mice implanted with PNP-expressing TNBC-EMT6 tumors, a single cycle of intratumoral PNP/F-araAMP therapy led to complete tumor regression and cure in all treated animals. Untreated contralateral tumors also exhibited anti-tumor responses following localized therapy.
2. Enhanced Checkpoint Inhibitor Activity
Subcurative F-araAMP doses combined with immune checkpoint inhibitors produced significant tumor burden reductions and complete regressions in otherwise resistant models. In vitro, PNP/F-araA initiated signaling cascades linked to immune sensitization, supporting the synergy observed in vivo.
3. Advancement Toward Combination Trials
These findings validate Gedeptin’s ability to remodel the tumor microenvironment and act as an immune-sensitization platform. GeoVax plans to advance Gedeptin into clinical trials in combination with checkpoint inhibitors, including pembrolizumab-based regimens, to broaden anti-tumor activity across solid tumor settings.
